tiprankstipranks
Trending News
More News >
COSMO Pharmaceuticals N.V. (CH:COPN)
:COPN
Switzerland Market

COSMO Pharmaceuticals N.V. (COPN) Stock Forecast & Price Target

Compare
2 Followers
See the Price Targets and Ratings of:

COPN Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
COSMO
Pharmaceuticals N.V.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

COPN Stock 12 Month Forecast

Average Price Target

CHF83.00
▲(33.66%Upside)
Based on 2 Wall Street analysts offering 12 month price targets for COSMO Pharmaceuticals N.V. in the last 3 months. The average price target is CHF83.00 with a high forecast of CHF100.00 and a low forecast of CHF66.00. The average price target represents a 33.66% change from the last price of CHF62.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"CHF52","101":"CHF101","64.25":"CHF64.3","76.5":"CHF76.5","88.75":"CHF88.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF83.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF66.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,64.25,76.5,88.75,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.7,61.87692307692308,65.05384615384615,68.23076923076923,71.40769230769232,74.58461538461539,77.76153846153846,80.93846153846154,84.11538461538461,87.2923076923077,90.46923076923076,93.64615384615385,96.82307692307693,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.7,60.56923076923077,62.43846153846154,64.3076923076923,66.17692307692307,68.04615384615384,69.91538461538462,71.78461538461539,73.65384615384616,75.52307692307693,77.3923076923077,79.26153846153846,81.13076923076923,{"y":83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.7,59.261538461538464,59.823076923076925,60.38461538461539,60.94615384615385,61.50769230769231,62.06923076923077,62.63076923076923,63.19230769230769,63.753846153846155,64.31538461538462,64.87692307692308,65.43846153846154,{"y":66,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":66.949,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.888,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.479,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.479,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.017,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.133,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.307,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.742,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.494,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.425,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.675,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.578,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF100.00Average Price TargetCHF83.00Lowest Price TargetCHF66.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CH:COPN
TipRanks AITipRanks
Not Ranked
TipRanks
CHF66
Buy
6.28%
Upside
Reiterated
06/06/25
COSMO Pharmaceuticals N.V. demonstrates strong financial performance with significant revenue and profit growth, supported by a robust balance sheet and cash flow generation. The stock's valuation appears attractive with a low P/E ratio and a solid dividend yield. However, the technical analysis indicates overbought conditions, which could temper near-term enthusiasm.
Kepler Capital  Analyst forecast on CH:COPN
Nicolas PauillacKepler Capital
Kepler Capital
CHF100
Buy
61.03%
Upside
Reiterated
07/01/25
COSMO Pharmaceuticals N.V. (0RGI) Receives a Buy from Kepler Capital
AI Firm
CHF64CHF66
Buy
6.28%
Upside
Reiterated
06/06/25
H.C. Wainwright Analyst forecast on CH:COPN
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
CHF133
Buy
114.17%
Upside
Reiterated
01/10/25
Cosmo Pharmaceuticals: Robust Financial Growth and Strategic AI Advancements Drive Buy Rating
Berenberg Bank Analyst forecast on CH:COPN
Unknown AnalystBerenberg Bank
Not Ranked
Berenberg Bank
CHF79
Buy
27.21%
Upside
Reiterated
11/11/24
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CH:COPN
TipRanks AITipRanks
Not Ranked
TipRanks
CHF66
Buy
6.28%
Upside
Reiterated
06/06/25
COSMO Pharmaceuticals N.V. demonstrates strong financial performance with significant revenue and profit growth, supported by a robust balance sheet and cash flow generation. The stock's valuation appears attractive with a low P/E ratio and a solid dividend yield. However, the technical analysis indicates overbought conditions, which could temper near-term enthusiasm.
Kepler Capital  Analyst forecast on CH:COPN
Nicolas PauillacKepler Capital
Kepler Capital
CHF100
Buy
61.03%
Upside
Reiterated
07/01/25
COSMO Pharmaceuticals N.V. (0RGI) Receives a Buy from Kepler Capital
AI Firm
CHF64CHF66
Buy
6.28%
Upside
Reiterated
06/06/25
H.C. Wainwright Analyst forecast on CH:COPN
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
CHF133
Buy
114.17%
Upside
Reiterated
01/10/25
Cosmo Pharmaceuticals: Robust Financial Growth and Strategic AI Advancements Drive Buy Rating
Berenberg Bank Analyst forecast on CH:COPN
Unknown AnalystBerenberg Bank
Not Ranked
Berenberg Bank
CHF79
Buy
27.21%
Upside
Reiterated
11/11/24
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering COSMO Pharmaceuticals N.V.

1 Month
xxx
Success Rate
7/14 ratings generated profit
50%
Average Return
+2.68%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +2.68% per trade.
3 Months
xxx
Success Rate
11/14 ratings generated profit
79%
Average Return
+9.29%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +9.29% per trade.
1 Year
Nicolas PauillacKepler Capital
Success Rate
9/14 ratings generated profit
64%
Average Return
+18.91%
reiterated a buy rating 12 days ago
Copying Nicolas Pauillac's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +18.91% per trade.
2 Years
xxx
Success Rate
9/14 ratings generated profit
64%
Average Return
+17.42%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +17.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

COPN Analyst Recommendation Trends

Rating
Jan 25
Mar 25
Apr 25
Jun 25
Jul 25
Strong Buy
2
3
4
4
3
Buy
3
5
3
3
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
8
7
7
4
In the current month, COPN has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. COPN average Analyst price target in the past 3 months is 83.00.
Each month's total comprises the sum of three months' worth of ratings.

COPN Financial Forecast

COPN Earnings Forecast

The previous quarter’s earnings for COPN were CHF3.37.
The previous quarter’s earnings for COPN were CHF3.37.

COPN Sales Forecast

The previous quarter’s earnings for COPN were CHF123.22M.
The previous quarter’s earnings for COPN were CHF123.22M.

COPN Stock Forecast FAQ

What is CH:COPN’s average 12-month price target, according to analysts?
Based on analyst ratings, COSMO Pharmaceuticals N.V.’s 12-month average price target is 83.00.
    What is CH:COPN’s upside potential, based on the analysts’ average price target?
    COSMO Pharmaceuticals N.V. has 33.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is COSMO Pharmaceuticals N.V. a Buy, Sell or Hold?
          COSMO Pharmaceuticals N.V. has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is COSMO Pharmaceuticals N.V.’s share price target?
            The average share price target for COSMO Pharmaceuticals N.V. is 83.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF100.00 ,and the lowest forecast is CHF66.00. The average share price target represents 33.66% Increase from the current price of CHF62.1.
              What do analysts say about COSMO Pharmaceuticals N.V.?
              COSMO Pharmaceuticals N.V.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of COSMO Pharmaceuticals N.V.?
                To buy shares of CH:COPN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis